70 / 80
68
19.- LARREY D. Epidemiology and individual susceptibi-
lity to adverse drug reactions affecting the liver. Semin
Liver Dis 2002; 22: 145-55.
20.- KOPANOFF DE, SNIDER DE JR, CARAS GJ. Iso-
niazid-related hepatitis. Am Rev Respir Dis 1978; 117:
991-1001.
21.- VAN DEN BRANDE P, VAN STEENBERGEN W,
VERVOORT G, DEMEDTS M. Aging and hepatotoxi-
city of isoniazid and rifampin in pulmonary tuberculo-
sis. Am J Respir Crit Care Med 1995; 152: 1705-8.
22.- VAN HEST, BAARS H, KIK S, VAN GERVEN P,
TROMPENAARS MC, KALISVAART N, et al. He-
patotoxicity of Rifampin-Pyrazinamide and Isoniazid
Preventive Therapy and Tuberculosis Treatment. Clin
Infect Dis 2004; 39: 488-96.
23.- GRONHAGEN-RISKA C, HELLSTROM PE, FRO-
SETH B. Predisposing Factors in Hepatitis Induced by
Isoniazid- Rifampin Treatment of Tuberculosis. Am Rev
Respir Dis 1978; 118: 461-6.
24.- WURWITZ N. Predisposing factors in adverse reactions
to drugs. Br Med J 1969: 1: 536.
25.- IWAINSKY H, WINSEL K, WERNER E, EULE H.
On the pharmacokinetics of rifampicin during treatment
with intermittent administration, Scand J Respir Dis
1976; 57: 5.
26.- FRANKS AL, BINKIN NJ, SNIDER DE JR, ROKAW
WM, BECKER S. Isoniazid hepatitis among pregnant
and postpartum Hispanic patients. Public Health Rep.
1989; 104: 151-5.
27.- GORDIN FM, COHN DL, MATTS JP, CHAISSON
RE, O’BRIEN RJ. For the Terry Beirn Hepatotoxicity of
Rifampin and Pyrazinamide in the Treatment of Latent
Tuberculosis Infection in HIV-Infected Persons: Is It
Different Than in HIV-Uninfected Persons? Clin Infect
Dis 2004; 39: 561-5.
28.- OHNO M, YAMAGUCHI I, YAMAMOTO I. Slow
N-acetyltransferase 2 genotype affects the incidence of
isoniazid and rifampicin-induced hepatotoxicity Int J
Tuberc Lung Dis 4: 256-61.
29.- PANDE JN, SINGH SPN, KHILNANI GC, KHILNANI
S, TANDON RK. Risk Factors for Hepatotoxicity from
Antituberculosis Drugs: a case-control study Thorax
1996; 51: 132-6.
30.- HUANG YS, CHEM HD, SU WJ WU JC, LAI SL,
YANG SY, et al. Polymorphism of the N-acetyltrans-
ferase 2 gene as a susceptibility risk factor for anti-
tuberculosis drug-induced hepatitis. Hepatology 2002;
35: 883-9.
31.- PARKIN DP, VANDENPLAS S, BOTHA FJH, VAN-
DENPLAS ML, SEIFART HI, VAN HELDEN PD, et
al. Trimodality of isoniazid elimination. Phenotype and
genotype in patients with tuberculosis. Am J Respir Crit
Care Med 1997; 155: 1717-22.
32.- MITCHELL JR, ZIMMERMAN HJ, ISHAK KG,
THORGEIRSSON UP, TIMBRELL JA, SNODGRASS
WR, et al. Isoniazid liver injury: clinical spectrum,
pathology and probable pathogenesis. Ann Intern Med
1976; 84: 181-92.
33.- TIMBRELL JA, MITCHELL JR, SNODGRASS WR,
NELSON SD. Isoniazid hepatotoxicity: The relationship
between covalent binding and metabolism in vivo. J
Pharmacol Exp Ther 1980; 213: 364-9.
34.- PERETTI E, KARLAGANIS G, LAUTERBURG BH.
Acetylation of acetylhydrazine, the toxic metabolite of
isoniazid, in humans. Inhibition by concomitant admi-
nistration of isoniazid. J Pharmacol Exp Ther 1987; 243:
686-9.
35.- LAUTERBURG BH, SMITH CV, TODD EL, MIT-
CHELL JR. Pharmacokinetcs of the toxic hydrazino me-
tabolites formed from isoniazid in humans. J Pharmacol
Exp Ther 1985; 235: 566-70.
36.- HUANG YS. Genetic polymorphisms of drug-metabo-
lizing enzymes and the susceptibility to antituberculosis
drug- induced liver injury. Expert Opin Drug Metab
Toxicol 2007; 3: 1-8.
37.- LÖNNROTH K, WILLIAMS B, STADLIN S, JA-
RAMILLO E, DYE C. Alcohol use as a risk factor for
tuberculosis-a systematic review. BMC Public Health
2008; 8: 289.
38.- WORLD HEALTH ORGANIZATION. Alcohol training
in general practice. EUR/ICP/ADA 038 (B). Copenha-
gen, Denmark: WHO, 1994.
39.- KOPANOFF DE, SNIDER D, CARAS G. Isoniazid
related hepatitis: a U.S. Public Health Service coopera-
tive surveillance study. Am Rev Respir Dis 1979; 117:
991-1001.
40.- HWANG SJ, WU JC, LEE CN, YEN FS, LU CL, LIN
TP, et al. A prospective clinical study of isoniazid-
rifampicin-pyrazinamide- induced liver injury in an area
endemic for hepatitis B. J Gastroenterol Hepatol 1997;
12: 87-91.
41.- COHN DL, CATLIN BJ, PETERSON KL, JUDSON
FN, SBARBARO JA. A 62-dose, 6-month therapy for
pulmonary and extrapulmonary tuberculosis: a twice-
weekly, directly observed, and cost-effective regimen.
Ann Intern Med 1990; 112: 407-15.
42.- SINGAPORE TUBERCULOSIS SERVICE/BRITISH
MEDICAL RESEARCH COUNCIL. Clinical trial of
three 6-month regimens of chemotherapy given inter-
mittently in the continuation phase in the treatment of
pulmonary tuberculosis. Am Rev Respir Dis 1985; 132:
374-8.
43.- MAHMOOD K, HUSSAIN A, JAIRAMANI KL, TA-
LIB A, ABBASI B, SALKEEN S. Hepatotoxicity with
antituberculosis drugs: the risk factors. Pak J Med Sci
2007; 23: 33-8.
44.- MORGAN FREIMAN J, JACOBSON KR, MUYIN-
DIKE WR, ROBERT HORSBURGH C, ELLNER
JJ, HAHN JA, et al. Isoniazid Preventive Therapy for
People with HIV who are Heavy Alcohol Drinkers in
High TB/HIV Burden Countries: A Risk-Benefit Analy-
sis. J Acquir Immune Defic Syndr. 2018; 77: 405-12.
F. Tirapegui S. et al.
Rev Chil Enferm Respir 2018; 34: 62-69